<DOC>
	<DOCNO>NCT01104155</DOCNO>
	<brief_summary>This Phase 2 , multicenter , randomize study two different dose regimen eribulin mesylate combination intermittent erlotinib patient previously treat , advance non-small cell lung cancer .</brief_summary>
	<brief_title>Eribulin Mesylate Combination With Intermittent Erlotinib Patients With Previously Treated , Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm nonsmall cell lung cancer ( NSCLC ) At least one prior platinumbased doublet anticancer treatment recurrent advance NSCLC Disease progression last anticancer therapy Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 Serum creatinine less equal 2.0 mg/dL creatinine clearance 40 mL/min accord Cockcroft Gault formula : Absolute neutrophil count great equal 1.5 x 10^9/L , hemoglobin great equal 10 g/dL ( corrected growth factor transfusion ) , platelet count great equal 100 x 10^9/L Total bilirubin less equal 1.5 time upper limit normal ( ULN ) alkaline phosphatase ( AP ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 time ULN ( case liver metastases less equal 5 time ULN ) . In case AP great 3 time ULN ( absence liver metastasis ) great 5 time ULN ( presence liver metastasis ) AND subject also know bone metastasis , liver specific AP must separate total use ass liver function instead total AP . At least one lesion great equal 1.5 cm long diameter nonlymph node great equal 1.5 cm shortest diameter lymph node serially measurable accord Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.17 Males female , age great equal 18 year Provide write informed consent Are willing able comply aspect protocol Females childbearing potential must negative serum betahuman chorionic gonadotropin ( BetahCG ) Visit 1 ( Screening ) negative urine pregnancy test prior start study drug ( Visit 2 ) . Female subject childbearing potential must agree abstinent use highly effective method contraception ( eg , condom + spermicide , condom + diaphragm spermicide , intrauterine device ( IUD ) , vasectomised partner ) start least one menstrual cycle prior start study drug throughout entire study period 30 day ( longer appropriate ) last dose study drug . Those woman use hormonal contraceptive must also use additional approve method contraception ( describe previously ) . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male subject abstinent undergone successful vasectomy , partner woman childbearing potential must use , partner must use highly effective method contraception ( eg , condom + spermicide , condom + diaphragm spermicide , IUD ) start least one menstrual cycle prior start study drug throughout entire study period 30 day ( longer appropriate ) last dose study drug . Those partner use hormonal contraceptive must also use additional approve method contraception ( describe previously ) . Exclusion criterion : Prior therapy eribulin tyrosine kinase inhibitor epidermal growth factor receptor Subjects brain subdural metastasis eligible , unless complete local therapy discontinue steroid indication great equal 4 week start study treatment . Symptoms attribute brain metastasis must stable great equal 4 week start study treatment ; radiographic stability determine compare contrastenhanced compute tomography ( CT ) magnetic resonance imaging ( MRI ) brain scan perform screen prior scan perform 4 week earlier . Existing anticancer therapyrelated toxicity grade great equal 2 , grade alopecia grade less equal 2 neuropathy , acceptable Current smoker stop smoke one week prior treatment study History congestive heart failure New York Heart Association ( NYHA ) Grade great II , unstable angina , myocardial infarction within past 6 month , serious cardiac arrhythmia Electrocardiogram QTc interval great equal 500 msec base upon Bazett 's formula ( QTcB ) Females pregnant ( positive BetahCG test ) breastfeeding Subject hypersensitivity eribulin /or erlotinib excipients Presence progressive central nervous system ( CNS ) disease , include degenerative CNS disease progressive tumor Subjects know human immunodeficiency virus ( HIV ) positive , neutropenia cause study treatment may make subject particularly susceptible infection Subjects active viral hepatitis ( A , B , C ) demonstrate positive serology Radiotherapy , chemotherapy , biological therapy investigational agent within 2 week prior start study treatment Meningeal carcinomatosis History drug alcohol dependency abuse within approximately last 2 year Medically unfit receive study drug unsuitable reason accord investigator judgment Any history concomitant medical condition , opinion Investigator , would compromise subject 's ability safely complete study Major surgery within 4 week start study treatment schedule surgery project course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>NSCLC</keyword>
</DOC>